stage IV follicular thyroid cancer
Showing 1 - 25 of >10,000
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic
Active, not recruiting
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma
- +25 more
- Laboratory Biomarker Analysis
- +3 more
-
Torrance, California
- +6 more
Jan 12, 2023
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
-
Washington, District of Columbia
- +6 more
Feb 2, 2023
Surgical Management of Advanced Thyroid Cancer
Recruiting
- Thyroid Carcinoma
- +6 more
- Thyroidectomy with or without lymphadenectomy or multivisceral resection
-
Rome, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 31, 2023
Pathological Manifestation in Thyroid Follicular Neoplasm: Early
Not yet recruiting
- Thyroid Cancer
- Follicular Thyroid Cancer
- (no location specified)
Jul 20, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
Thyroglobulin and Galectin-3 for Prognosis and Follow-up in
Recruiting
- Thyroid Cancer
- +2 more
-
Taipei, TaiwanChih-Yuan Wang, M.D
Oct 16, 2022
Studies on Tumors of the Thyroid
Recruiting
- Hurthle Cell Thyroid Cancer
- +4 more
- 68-Gallium Dotatate
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)
Not yet recruiting
- Thyroid Cancer
- +5 more
- Selpercatinib
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Dec 20, 2022
18F-TFB PET/CT Scan in Differentiated Thyroid Cancer
Recruiting
- Differentiated Thyroid Gland Carcinoma
- +2 more
- Computed Tomography
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1
Active, not recruiting
- Ann Arbor Stage II Grade 1 Follicular Lymphoma
- +12 more
- Lenalidomide
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV Trial in Australia (BMS-986369,
Not yet recruiting
- Follicular Lymphoma Stage II
- +2 more
- BMS-986369
- +2 more
-
Ballarat, Victoria, Australia
- +4 more
Mar 15, 2023
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,
Recruiting
- BRAF NP_004324.2:p.V600M
- +6 more
- Binimetinib
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Aug 17, 2022
Benign Thyroid Gland Tumor, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Follicular Tumor of Uncertain Malignant Potential
Recruiting
- Benign Thyroid Gland Neoplasm
- +4 more
- Quality-of-Life Assessment
- Radiofrequency Ablation
-
Houston, TexasM D Anderson Cancer Center
Sep 3, 2022
Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma
Recruiting
- Refractory Thyroid Gland Carcinoma
- +3 more
- 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
- +2 more
-
Xiamen, ChinaThe First Affiliated Hospital of Xiamen University
Nov 3, 2022
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 3, 2022
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Completed
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Laboratory Biomarker Analysis
- +2 more
-
Mountain View, California
- +90 more
Aug 3, 2022
Thyroid Cancer Stage IV, Radiation Toxicity Trial in Mumbai (Intensity Modulated Radiotherapy, Surgery alone)
Active, not recruiting
- Thyroid Cancer Stage IV
- Radiation Toxicity
- Intensity Modulated Radiotherapy
- Surgery alone
-
Mumbai, Maharashtra, IndiaGouri Pantvaidya
Apr 29, 2022
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +3 more
- Clinical Observation
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Thyroid Cancer Trial in Suita (Targeted alpha therapy)
Recruiting
- Thyroid Cancer
- Targeted alpha therapy
-
Suita, JapanOsaka University Hospital
Mar 2, 2022
Follicular Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Tocilizumab, Lenalidomide)
Recruiting
- Follicular Lymphoma
- Mosunetuzumab (IV)
- +3 more
-
Duarte, California
- +21 more
Jan 10, 2023
Thyroid Tumor Follicular, Bone Metastases Trial in Beijing (Sr-89)
Not yet recruiting
- Thyroid Neoplasm Follicular
- Bone Metastases
-
Beijing, ChinaPeking Union Medical College Hospital
Jul 18, 2022
Malignant Female Reproductive System Tumor, Stage III Cervical Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8 Trial in Duarte
Not yet recruiting
- Malignant Female Reproductive System Neoplasm
- +10 more
- Discussion
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 24, 2023
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical
Not yet recruiting
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- +11 more
- Acupressure Therapy
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 12, 2023